Large-scale manufacturing helps AMRI's top line

CDMO Albany Molecular Research ($AMRI) said large-scale manufacturing revenue was up 14% to $29.3 million in its third quarter and total contract revenue was up 4% to $45.6 million. Still, it wasn't enough to pull the company into the black. The Albany, NY-based company reported a loss of $2.14 million, which was a significant improvement over the $5.9 million loss reported a year earlier. Royalty payments it receives for the API in the antihistamine Allegra, were also up sharply to $9.4 million, a 45% bump, the company said. Revenue from development and small-scale manufacturing fell in the quarter to $7.4 million, a 20% decline over last year. Release | More

Suggested Articles

Pfizer says two lots of migraine med Relpax failed to meet microbial standards and may be contaminated with genera pseudomonas and burkholderia.

Emcure has had its share of run-ins with the FDA in the past over the sterility of its plants. Now, it can notch one more black mark on its belt.

The FDA has slapped a warning letter on an Indian solvent recycler that may have contributed to the contamination of blood pressure meds.